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Abstract
Background: Autism spectrum disorder (ASD) is one of the most highly heritable neuropsychiatric disorders, but
underlying molecular mechanisms are still unresolved due to extreme locus heterogeneity. Leveraging meaningful
endophenotypes or biomarkers may be an effective strategy to reduce heterogeneity to identify novel ASD genes.
Numerous lines of evidence suggest a link between hyperserotonemia, i.e., elevated serotonin (5-hydroxytryptamine
or 5-HT) in whole blood, and ASD. However, the genetic determinants of blood 5-HT level and their relationship to
ASD are largely unknown.
Methods: In this study, pursuing the hypothesis that de novo variants (DNVs) and rare risk alleles acting in a recessive
mode may play an important role in predisposition of hyperserotonemia in people with ASD, we carried out whole
exome sequencing (WES) in 116 ASD parent-proband trios with most (107) probands having 5-HT measurements.
Results: Combined with published ASD DNVs, we identified USP15 as having recurrent de novo loss of function
mutations and discovered evidence supporting two other known genes with recurrent DNVs (FOXP1 and KDM5B).
Genes harboring functional DNVs significantly overlap with functional/disease gene sets known to be involved in ASD
etiology, including FMRP targets and synaptic formation and transcriptional regulation genes. We grouped the
probands into High-5HT and Normal-5HT groups based on normalized serotonin levels, and used network-based gene
set enrichment analysis (NGSEA) to identify novel hyperserotonemia-related ASD genes based on LoF and missense
DNVs. We found enrichment in the High-5HT group for a gene network module (DAWN-1) previously implicated in
ASD, and this points to the TGF-β pathway and cell junction processes. Through analysis of rare recessively acting
variants (RAVs), we also found that rare compound heterozygotes (CHs) in the High-5HT group were enriched for loci
in an ASD-associated gene set. Finally, we carried out rare variant group-wise transmission disequilibrium tests (gTDT)
and observed significant association of rare variants in genes encoding a subset of the serotonin pathway with ASD.
Conclusions: Our study identified USP15 as a novel gene implicated in ASD based on recurrent DNVs. It also
demonstrates the potential value of 5-HT as an effective endophenotype for gene discovery in ASD, and the
effectiveness of this strategy needs to be further explored in studies of larger sample sizes.
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Background
Autism spectrum disorder (ASD) is an early-onset neu-
rodevelopmental condition with an estimated prevalence
of ~1 in 68 [1]. ASD is expressed across a spectrum of
severity in two core phenotypic domains: persistent defi-
cits in social interaction and communication and re-
stricted, repetitive behaviors and interests. ASD is highly
heritable, with an estimated heritability of 64–91% based
on a recent meta-analysis [2]. The genetic basis of ASD,
however, is complicated by locus heterogeneity for both
common allele and rare variant effects. Although com-
mon variants in aggregate contribute to a larger propor-
tion (~50%) of liability [3], genome-wide association
studies (GWAS) with thousands of subjects have not
found consistent, strongly associated individual common
variants [4–9]. Rare de novo variants, including both
copy number (CNVs) and single nucleotide variants
(SNVs), play a significant role in ASD liability [10]. To
date, dozens of genes harboring de novo CNVs and
SNVs meeting genome-wide significance have been iden-
tified, and corresponding functional pathways and bio-
logical processes have emerged from analysis of these
variants [10]. Despite advances in identifying ASD risk
loci, major hurdles remain, since rare variants account
for only a minority of cases, and effect sizes for common
variants necessitate GWAS sample sizes many times
those currently available. Data indicate that a thousand
or more genes may contribute to ASD liability [11].
In addition to larger samples, another strategy to tackle
heterogeneity leverages meaningful endophenotypes or
biomarkers that demonstrate heritability [12, 13]. The hy-
pothesis that endophenotypes reflect variation in a subset
of the broader set of disease risk genes leads to the notion
that the subgroup of cases that share the endophenotype
is more genetically homogeneous. Thus, gene discovery in
such a subgroup affords greater power compared with a
similarly sized group from the overall disease population
and in the case of molecular traits may provide a more
direct path to functional mechanisms. Biomarkers and
endophenotypes in ASD have drawn interest given the po-
tential to facilitate earlier diagnosis and better prediction
of prognosis or treatment response [14].
Hyperserotonemia, or elevated serotonin (5-hydroxy-
tryptamine or 5-HT) in whole blood, is one of the most
consistent quantitative traits and biomarkers in ASD
since its identification in 1961 [15–18]. In particular,
these studies reported a significantly higher 5-HT blood
level in about one third of ASD subjects, compared with
typically developing controls. The elevated 5-HT level,
or hyperserotonemia, is observed in ASD but not in sub-
jects with unspecified intellectual disability [19]. Whole
blood 5-HT levels show intermediate elevation in first-
degree relatives of hyperserotonemic probands [20–23].
While hyperserotonemia in ASD shows evidence for
heritability, whole blood 5-HT also exhibited high nar-
row and broad heritability (0.51 and 1.0, respectively) in
a Hutterite population sample [24]. Although the mech-
anism underlying the elevation of serotonin levels in
ASD remains unclear, several lines of investigation point
to a role for serotonin in ASD etiology [25–29]. In
blood, greater than 99% of the serotonin is stored in
platelets, which is taken up from the enterohepatic cir-
culation by the serotonin transporter (SERT), encoded
by SLC6A4, after synthesis in enterochromaffin cells of
the gut. Linkage studies in ASD have implicated the
17q11.2 region harboring SLC6A4 [30–32]. Hypothesiz-
ing rare variants in the absence of significant allelic asso-
ciation at SLC6A4 led to the discovery of multiple
functional coding variants [30], and in particular, the as-
sociation of SERT Ala56 was supported in mice by the
evidence that mice carrying the variant displayed alter-
ations in social function, communication, and repetitive
behavior and elevated whole blood 5-HT [33]. These
findings collectively support hyperserotonemia as a
powerful endophenotype for dissecting the genetic eti-
ology of ASD.
In this study, we carried out whole exome sequencing
(WES) in a collection of ASD parent-proband trios with
5-HT measurements collected through an Autism
Center of Excellence (ACE) study to search for genetic
variants implicated in ASD using serotonin as an endo-
phenotype. Given that elevated serotonin was observed
in ASD probands compared with their parents, we
hypothesize that de novo variants (DNVs) and reces-
sively acting variants (RAVs) play a key role in predis-
position of hyperserotonemia and ASD. DNVs observed
in probands, but not parents, which disrupt genes in-
volved in 5-HT and ASD, should affect 5-HT levels only
in probands; similarly, rare risk alleles acting in a reces-
sive manner (i.e., RAVs) that are transmitted from par-
ents to probands may lead to elevated 5-HT levels in
those probands. Both DNVs and RAVs have been impli-
cated in ASD [34]; however, the allelic architecture of
hyperserotonemia in autism is unknown. We thus aimed
to utilize this unique endophenotype in ACE trios to
identify genes involved in both traits; an approach that
we hypothesize effectively reduces genetic heterogeneity.
Moreover, we predict that positive findings will shed
light on what serotonin-related functional pathways are
involved in ASD. Corresponding genes and proteins may
offer insights into dysregulated CNS development and
point to therapeutic strategies for ASD symptoms.
Methods
Whole exome sequencing and data processing
Exome capture and sequencing were conducted at the
Center for Inherited Disease Research (CIDR) and
HudsonAlpha (11 trios). Genomic DNA was extracted
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from either cell line or blood samples collected from all
participating family members in ACE. At HudsonAlpha,
exons were captured using NimbleGen Seq Cap EZ SR
v2 (Roche, Switzerland) and sequenced on an Illumina-
HiSeq2000 (Illumina, USA). At CIDR, exons were
captured using Agilent SureSelect XT HumanAllExon
V5 + UTRs_71MbKit_S04380219 (Agilent Technologies,
USA). Sequencing platform and chemistry was Illumina
HiSeq2500 (Illumina, USA), TruSeq Rapid PE Cluster
Kit-HS (Illumina, USA), and TruSeq Rapid SBS-HS (Illu-
mina, USA) with 100 bp paired-end runs at ~60×. Se-
quencing reads were aligned to the reference human
genome GRCh37 using BWA [35] with default settings.
Next, the resulting BAM files were further processed
and used for variant calling following the best practice
procedures of GATK [36, 37]. We retained biallelic
SNVs with PASS VQSR tag and average depth >10. We
masked genotypes of trios with minimal depth <6 as
missing. We annotated all variants using ANNOVAR
[38] and obtained deleteriousness predictions from nine
bioinformatics tools provided in ANNOVAR. Each vari-
ant was assigned a deleterious score (DScore) between 0
and 9, denoting the number of damaging predictions
from among these algorithms. We used TrioDenovo to
call DNVs on both autosomes and X chromosome and
obtained reliable candidates for validation after filtering
[39]. We focused on two types of functional variants:
loss of function (LoF; splice site, nonsense, and frame-
shift) and missense (Mis) DNVs. We experimentally vali-
dated all functional DNVs by Sanger sequencing and
obtained 100 validated functional DNVs, including 16
LoF and 84 Mis DNVs across 99 genes (Additional file 1:
Table S1).
In RAV analysis, we obtained 2073 LoF and 39,095
Mis-D4 SNVs after filtering. To get reliable RAVs, we
used the phase-by-transmission algorithm to construct
haplotypes in trios to achieve robust phasing for rare
variants [40].
Normalization of whole blood serotonin
In order to compare whole blood serotonin (WB5HT)
values across age and population groups, z-scores
were generated to adjust for pubertal status and race/
ethnicity. Pubertal status was determined based on
their Tanner stage [41, 42] or chronological age. Sub-
jects were classified as pre-pubertal if their Tanner
stage was either I or II and post-pubertal if their Tan-
ner stage was greater than or equal to III. In the case
of missing Tanner data, chronological age was used to
create the puberty variable. Subjects with a chrono-
logical age less than 144 months were classified as
pre-pubertal, whereas subjects whose chronological
age were greater than or equal to 144 months were
classified as post-pubertal.
Race and ethnicity information was obtained during
an initial screening by parent report. A subject’s reported
race and ethnicity was classified based on self-report and
confirmed by principal components analysis (PCA). Util-
izing the respective ancestry group, means and standard
deviations (SD) for WB5HT of the pre-pubertal, “normal
control” children generated previously, WB5HT z-scores
were calculated for our pre-pubertal subjects. For post-
pubertal subjects, WB5HT z-scores were generated from
the WB5HT means and SDs of the adult subjects in [43]
(see Additional file 1: Table S2). For subjects with more
than one reported race/ethnicity, the average of the re-
spective means and SDs were used to calculate their z-
score. Individual subjects taking medications that could
potentially influence serotonin as well as other psycho-
tropic medications were excluded from WB5HTanalyses.
After normalization, we separated probands into
two groups based on the distribution of WB5HT-z in
parents and probands (Additional file 2: Figure S1).
Specifically, we classified probands with WB5HT-z
>1.75 as the High-5HT group and probands with
WB5HT-z <1 as the Normal-5HT group, with 30 and
67 probands in the High-5HT and Normal-5HT
groups, respectively. For analysis of WB5HT-z sub-
groups, we did not include the 10 probands (and cor-
responding genes) who had values between 1 and
1.75 to increase separation between comparison
groups, given the absence of an obvious cut-point for
defining hyperserotonemia.
RAV burden in High-5HT group vs. Normal-5HT groups
For RAV analysis, we carried out PCA on our data com-
bined with the 1000 Genomes Project data and selected pro-
bands of Western European descent (25 High-5HT and 38
Normal-5HT) based on the first two PCs to avoid con-
founds caused by population stratification (Additional file 3:
Figure S2). We called two types of RAVs from our data:
compound heterozygotes (CHs) and homozygotes. A total
of 179 RAVs (137 CH and 42 homozygote genotypes—and
corresponding 155 genes—were present in 78 WE probands.
Of these RAV genes, 127 are expressed (RPKM >1) in early
fetal brain using data from Brainspan (Brainspan: http://
www.brainspan.org/).
For each gene detected, we carried out the Fisher exact
test of RAVs in the High-5HT vs. the Normal-5HT groups.
Given the low power to detect significant associations of
individual genes, we selected genes with an odds ratio >1
as candidates for the risk RAV genes in the High-5HT
group and used genes with OR <1 as controls.
Gene set enrichment analysis
We identified several functional/disease gene sets in
ASD for gene set enrichment analysis (GSEA): (1) two
lists of RBFOX1 (RNA-binding protein, fox-1 homolog
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1)-regulating RNA targets: RBFOX1-1 [44]; RBFOX1-2
[45]; (2) two lists of fragile X mental retardation protein
(FMRP) mRNA targets: FMRP-1 [46]; FMRP-2 [47]; (3)
evolutionarily constrained genes (ECGs) [48]; (4)
synapse-related gene lists: postsynapse-related genes
from proteomic profiling of human neocortical biopsies
(Hpsd), protein complexes of the postsynaptic density
(PSD; PSD-95, ARC, mGluR5, NMDAR), and genes re-
lated to presynaptic proteins, presynaptic active zone,
and synaptic vesicles [49, 50]; (5) chromatin remodeling
factors (CRFs) [51]; (6) histone modification enzymes
(HMEs) [52]; (7) differentially expressed genes from cor-
tical samples of autism (DEs) [44]. All genes including
candidates and known gene sets were mapped to current
human gene symbols (HGNC) to assure the consistency
of nomenclature.
It is well known that, generally, brain-expressed
genes tend to be longer, and if a statistic is influenced
by gene length, then gene length is a potentially con-
founding factor for GSEA (Additional file 4: Figure
S3). For both DNVs and RAVs, to control for the
confounding nature of gene length, we used a sam-
pling scheme to obtain empirical p values. Specifically,
we constructed a null distribution of the number of
overlapping genes by randomly sampling genes
matching the length of the candidate genes and then
calculated empirical p values by comparing the ob-
served overlapping gene number to the null distribu-
tion. To select a gene with matching length, we
sorted genes by their coding sequence (CDS) lengths
and randomly picked a gene from the neighbors of
target gene. The interval of neighbors is a parameter
that may affect the results, e.g., an interval of 30
means that we chose a gene from a subset of genes
consisting of 30 shorter and 30 longer neighbors of
the target gene. We therefore tested simulated config-
urations with 30, 100, or 1000 neighbors and obtained
similar results across all simulated sets. We present
the results using an interval of 100.
Network-based gene set enrichment analysis
Our approach to the network-based gene set enrich-
ment analysis (NGSEA) is based on the guilt-by-
association principle, in that genes underlying risk
for a given disease tend to function together in one
or more functional, biological networks. This as-
sumption underlies many approaches that have been
successfully applied to search for disease genes in
numerous disorders, including ASD [53–55]. Given
the extensive heterogeneity of ASD, it is expected
that several different networks underlying its etiology
exist. To test the hypothesis that a candidate (ACE)
gene set is enriched for associated genes, we
reframed this hypothesis as being that novel gene
candidates identified from our ACE sample are
closer to established ASD genes in the network than
expected by chance. Accordingly, we devised a
network-based approach to measure the distance be-
tween two gene sets, similar to EnrichNet [56], and
used a sampling scheme to assess the significance.
The framework assigns genes in a known ASD gene set as
seeds in a functional protein-protein interaction network
and then runs label propagation in the network using a
random walk with restart [57, 58]. Briefly, let A be an
adjacent matrix representing the gene-gene network,
with 1 in the matrix indicating that the corresponding
two genes interact and 0 otherwise, m be the number
of genes in the network, F0 be a vector of length m
with the ith element being 1 if the ith gene is a seed
gene and 0 otherwise. Label propagation is executed
as Ft+1 = (1 − α) × A × Ft + α × F0 until convergence,
with α being the restart rate. Following propagation,
each value in F represents the influence (i.e., the
amount of flow) the corresponding gene receives from
the seeds; we termed this influence the propagation-
based distance in network (PDN) to measure the dis-
tance between a candidate gene and a known ASD
gene set (i.e., the seeds). Next, we summed the PDN
of all novel candidate genes to a known ASD gene
set and used the sum as a measurement of the dis-
tance between the candidate set and the known gene
set. Finally, we generated pseudo-candidate gene sets
by randomly sampling genes from the human gen-
ome, controlling for gene length as in the GSEA, and
then calculated the sum of the PDN between pseudo
sets to the known ASD gene set to build the null dis-
tribution; this in turn permits the generation of em-
pirical p values. We used the PINA [59] network in
this analysis with a restart probability of 0.3.
Rare variant group-wise transmission/disequilibrium test
We collected a set of serotonin-related genes, repre-
senting both pre- and postsynaptic functions, includ-
ing 5-HT metabolism, transport, and signaling
(Additional file 1: Table S3). We assigned genes in 5-
HT receptor family as a group (Receptor group) and
genes related to 5-HT metabolism, transport, and
other largely presynaptic functions as the other group
(Non-Receptor group) due to their distinct mecha-
nisms. We carried out group-wise transmission/dis-
equilibrium test (gTDT) on each of the two groups
to test whether rare variants in these genes are asso-
ciated with ASD. We kept all LoF and Mis-D4
(Dscore ≥4) variants with MAF <0.01 located on au-
tosomes; in this analysis we used a more stringent
criterion of Mis-D4 than Mis-D2 used in DNVs to fil-
ter missense variants here to potentially enrich for
causal variants.
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Results
Brief description of samples and sequence data
processing
We sequenced the exomes of 133 trios as a part of the
University of Illinois at Chicago ACE project. To avoid
confounding our analysis with data from earlier studies,
17 trios that were included in previously published data
[60] were excluded, and the remaining 116 trios were
used in subsequent analyses. Detailed information on
subject ascertainment and clinical assessment has been
described elsewhere [61]. For this analysis, one subject
with Fragile X syndrome was excluded but three subjects
with clinically significant CNVs (A2BP1/RBFOX1 dele-
tion [62] (1.0 <WB5HT-z < 1.75), maternal interstitial
duplication 15q11-q13 (Normal-5HT group), and
NRXN3 deletion (Normal-5HT group)) were included.
Demographic and phenotypic data are summarized in
Additional file 1: Table S4. As expected, males were
overrepresented with a ratio of 5.44:1 (male:female),
which is comparable to the general ASD population
[63]. Of the 116 analyzed trios, 107 probands, 72 fathers
and 63 mothers had 5-HT measurements. An overview
of analyses conducted in this study is presented in Fig. 1.
Analysis of de novo variants
Recurrence of LoF DNVs
We first focused on LoF DNVs as it is well established that
rare LoF DNVs can exert large effect sizes on risk of ASD
and are more readily detected compared with other types
of variants [11, 64]. Considering the stronger purifying se-
lection conferred by LoF mutations, recurrence of rare LoF
DNVs in a specific gene is a strong indicator of disease as-
sociation, and recurrence of two or more LoF DNVs in a
gene typically reaches genome-wide significance for a sam-
ple size up to 3000 families [65]. We did not observe genes
with recurrent LoF DNVs in our data given the limited
sample size. We then compared genes implicated by our
DNVs to those from other recent studies, such as the 192
LoF DNVs from the Autism Sequencing Consortium
(ASC) [11] and 391 LoF DNVs from the Simons Simplex
Collection (SSC) [64]. When combined with previous data-
sets, our study identified a second LoF DNV in ubiquitin-
specific peptidase 15 (USP15) making this the first reported
recurrence of LoF DNV in this gene, implicating it as a
novel ASD candidate. A frameshift DNV was also identi-
fied in FOXP1 (forkhead box P1) and a stop-gain mutation
in KDM5B (lysine demethylase 5B), adding further support
for these two loci already identified as having recurrent, in-
dependent DNVs (N ≥ 2) within SSC or ASC data. Thus,
our studies provide strong support for three loci as high
confidence ASD (hcASD) genes based on LoF DNVs.
Enrichment analysis of DNVs in functional gene sets
We restricted analysis to the genes that are expressed at
early stages of brain development (Brainspan, http://
www.brainspan.org/) using a criterion of RPMK >1 (16
Fig. 1 Overview of the analysis. This study shows the analysis of DNVs and RAVs in 116 families with serotonin measurement. The major steps are shown
in the middle (green). The analysis steps identifying ASD-related signals used the whole DNV/RAV list (yellow). The steps identifying 5HT-related signals in
ASD used DNVs/RAVs in High-5HT vs. Normal-5HT groups (blue). ACE, Autism Center of Excellence; DNV, de novo variant; RAV, recessive acting variant;
LoF, loss of function; GSEA, Gene Set Enrichment Analysis; NGSEA, Network-based Gene Set Enrichment Analysis; 5HT, 5-hydroxytryptamine; TADA, a list
from a recent study of both transmitted and de novo variants in ASD [11]; CH, compound heterozygote; Hz, homozygote
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LoFs and 70 Mis). We first focused on LoF DNVs and the
results are shown in Table 1. Note that for the analyses car-
ried out in this study, we report the nominal p values, not
corrected for multiple comparisons. We found the most
significant enrichment of LoF DNV genes in the HME gene
set (p = 0.009), of which KDM5B is a notable example. LoF
DNV loci did not show significant enrichment in the two
FMRP target gene sets (p = 0.415/0.157). FMRP functions
as a translational repressor in neurons, and loss of FMRP
function causes fragile X syndrome [66–68]. RBFOX1 (pre-
viously known as Ataxin-2-binding protein 1, A2BP1) cor-
responds to the only known splicing factor implicated in
ASD, and hemizygous loss of RBFOX1 is associated with
ASD and multiple epilepsy syndromes [69]. However, we
saw no significant enrichment among its targets (p = 1 and
0.522). We also did not observe significance enrichment of
LoF DNVs in genes under evolutionary constraint (ECGs;
p = 0.132) and synaptic protein gene sets.
In testing for enrichment of missense DNV-containing
genes with the same functional gene sets, we observed
enrichment in FMRP targets and Hpsd (Table 1). When
combining missense and LoF DNVs together, signifi-
cance for FMRP, Hpsd, and HME gene was observed
(Table 1). We then combined the LoF DNVs with the
SSC and ASC studies to get a comprehensive picture of
enrichment in functional/disease gene sets. Consistent
results are shown in Additional file 1: Table S5, i.e.
RBFOX1-2, FMRP targets, ECGs, Presynaptic genes, and
HMEs show strong levels of significance.
Gene set enrichment analysis of DNVs in known ASD risk
gene sets
Next we investigated to what degree our DNVs identify
known ASD risk genes. We collected two ASD gene sets:
(1) candidates identified from allelic association studies,
rare single gene variants (CNVs and SNVs), and genes
linked to syndromic autism, all of which are cataloged in
AutDB updated on June, 2015 [70]; (2) genes with recur-
rent DNVs combining data from ASC and SSC (Recur)
[11, 64]—we consider the latter to represent a carefully
chosen set of hcASD risk genes. Indeed, we found that
genes with LoF DNVs are significantly enriched amongst
Recur (p = 3.817 × 10−4) genes (Table 2). The results
confirm that LoF DNVs in the ACE trio sample corres-
pond to genes with extant evidence for involvement in
ASD risk. In contrast, Mis-D2 DNVs only showed a
nonsignificant trend in Recur (p = 0.096) and no evi-
dence for enrichment among AutDB genes (p = 0.161)
(Table 2).
We asked how the signals shown above relate to the
distribution of whole blood serotonin by comparing
GSEA results of DNV genes in the High-5HT and
Normal-5HT groups. Since serotonin level is influenced
by several factors like ancestry, age, and pubertal status,
we first calculated a normalized z-score for each of the
probands, adjusting for ethnicity and age, and assigned
to High-5HT or Normal-5HT groups based on a logical
split in the distribution (“Methods”). The corresponding
gene lists are provided in Additional file 1: Table S6.
While the LoF DNVs in the normal-5HT group are sig-
nificantly enriched in both ASD-associated genes
(AutDB: p = 0.036, Recur: p = 8.989 × 10−5), LoF DNV
genes in the High group showed no such evidence of en-
richment (Table 2). Contrasting the Normal-5HT group,
we observed no significant enrichment of Mis-D2 DNV
genes in the High-5HT group (Table 2).
To further explore our data and map observed DNVs
onto biological networks, we tested two gene network
constructs previously employed to identify gene net-
works associated with ASD based on enrichment of rare,
damaging variants: three modules (denoted as MAGI-1,
2, 3; for Merging Affected Genes into Integrated net-
works) reported in [55] and four modules (denoted as
Table 1 GSEA of DNVs in functional/disease clusters implicated
in ASD (italics: p < 0.05)
Func (86)a LoFs (16) Mis (70)
RBFOX1-1 (186) 2 (0.342) 0 (1) 2 (0.318)
RBFOX1-2 (547) 5 (0.469) 1 (0.522) 4 (0.542)
FMRP-1 (936) 15 (0.045) 2 (0.415) 13 (0.045)
FMRP-2 (831) 13 (0.136) 3 (0.157) 10 (0.256)
ECGs (928) 10 (0.341) 3 (0.132) 7 (0.598)
Hpsd (1429) 15 (0.021) 3 (0.181) 12 (0.027)
PSD-95 (107) 1 (0.392) 0 (1) 1 (0.348)
ARC (25) 0 (1) 0 (1) 0 (1)
mGluR5 (37) 0 (1) 0 (1) 0 (1)
NMDAR (59) 0 (1) 0 (1) 0 (1)
Presynaptic active zone (204) 1 (0.498) 0 (1) 1 (0.457)
Presynaptic (330) 3 (0.252) 1 (0.239) 2 (0.421)
Vesicles (104) 1 (0.367) 0 (1) 1 (0.281)
CRFs (55) 1 (0.358) 0 (1) 1 (0.361)
HMEs (146) 4 (0.023) 2 (0.009) 2 (0.301)
DEs (411) 2 (0.461) 1 (0.268) 1 (0.707)
aThe number in the header and row names denotes the size of the list. The
number of overlapped genes between candidate DNVs and functional/
diseases gene sets and p value (in brackets) are listed in main cells
Table 2 GSEA of DNVs with known ASD risk gene sets
(italics: p < 0.05)
AutDB (781) Recur (37)
LoFs (16) 2 (0.124) 2 (3.817e−04)
Mis-D2 (56) 4 (0.161) 1 (0.096)
High-5HT_LoFs (5) 0 (1.000) 0 (1.000)
High-5HT_Mis-D2 (10) 0 (1.000) 0 (1.000)
Normal-5HT_LoFs (8) 2 (0.036) 2 (8.989e−05)
Normal-5HT_Mis-D2 (38) 3 (0.179) 1 (0.067)
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DAWN-1, 2, 3, 4, for Detecting Association with Net-
works) reported in [11]. Testing genes with de novo LoF
or Mis-D2 variants from High-5HT (N = 5, 10) or
Normal-5HT (N = 8, 38) groups against the three mod-
ules in the MAGI classification, showed no significant
enrichment (Table 3). However, using the DAWN mod-
ules against DNV loci from the Normal-5HT group, we
found significant overlap of LoF genes in DAWN-4 (p =
9.216 × 10−6), Mis-D2 genes in DAWN-1 (p = 0.035) and
DAWN-3 (p = 5.280 × 10−3) (Table 3). This suggests
that genes harboring functional DNVs from the
(major) normal 5-HT part of the ACE cohort are
enriched for ASD genes falling into these particular
modules. In contrast, no evidence for enrichment was
detected for the High-5HT group.
Identification of novel ASD genes through network-based
analysis of DNVs
We were particularly interested in assessing to what de-
gree the novel DNV genes identified in our study osten-
sibly contribute to ASD risk, which cannot be assessed
by GSEA, and thus applied NGSEA to further this goal.
We note that NGSEA in this section used the same
functional/disease gene sets and network modules, with
the exception that the current analyses specifically test
for novel signals in network space, while traditional en-
richment analysis does not. No enrichment, however,
was detected considering either Recur or AutDB sets, or
the seven total MAGI/DAWN modules, for both LoF
and Mis-D2 DNV genes (Table 4).
Next we aim to inspect whether NGSEA can discover
novel signals with the aid of whole blood 5-HT as an
endophenotype. Results show that neither group of LoF
genes were significantly closer to any of the MAGI mod-
ules than expected by chance, with only the exception
that Mis-D2 of Normal-5HT group is significantly closer
to MAGI-1 (Table 4). We did, however, observe signifi-
cance for DAWN-1 LoF genes in the High-5HT group
(p = 0.039, Fig. 2); Normal-5HT LoF loci were not asso-
ciated with any DAWN modules (Table 4). Relating re-
sults from GSEA and NGSEA analyses, data indicate
that High-5HT and Normal-5HT LoF genes identify dif-
ferent modules, i.e., High-5HT LoF genes identify
DAWN-1 using NGSEA (Table 4), and the Normal-5HT
LoF genes detect DAWN-4 using GSEA (Table 3). The
complete list of the LoF DNV genes in the High-5HT
group is presented in Additional file 1: Table S6 and
their enrichment findings for different gene modules are
shown in Table 4.
Like with LoF mutations, NGSEA of Mis-D2 DNV
genes from the High-5HT group also revealed enrich-
ment with DAWN-1 (p = 0.04, Fig. 3). However, the
Normal-5HT Mis-D2 genes still showed no enrichment
to DAWN modules (Table 4). In contrast to the consist-
ent pattern of NGSEA enrichment of High-5HT DNV
genes among DAWN-1, genes identified by Normal-
5HT DNVs, which showed no enrichment using
NGSEA, were enriched in DAWN-1, DAWN-3, and
DAWN-4 modules in GSEA.
Analysis of rare recessively acting variants
In parallel with DNVs, we hypothesize that the elevated
5-HT in probands compared to their parents is partially
accounted for by rare recessively acting variants (RAVs),
consisting of compound heterozygotes (CHs) and homo-
zygotes. We focused on functional variants, comprising
all LoF and Mis-D2 variants on autosomes with minor
allele frequency (MAF) <0.01; we excluded X chromo-
somes in the RAV analysis due to its inapplicability in
males. We used the phase-by-transmission algorithm to
construct haplotypes in trios to achieve robust phasing
for rare variants [40], and in total, we obtained 137 CHs
and 42 homozygotes in probands, distributed in 155
genes. We combined both the CHs and homozygotes for
the analysis of RAVs.
RAV burden associated with ASD
We first examined whether probands carry a higher bur-
den of RAVs compared to their parents. As the number
of RAVs in a given sample and across samples is influ-
enced by sequencing data in complex ways, we normal-
ized functional RAV burden using synonymous RAV
burden as a baseline, assuming that synonymous vari-
ants do not (by and large) confer ASD risk. Results show
that the burden of functional RAVs in probands is not
significantly different from that in parents (Additional
file 5: Figure S4). We further examined whether genes
with RAVs in probands are enriched in functional/
Table 3 GSEA of DNVs in High-5HT and Normal-5HT groups with network modules implicated in ASD (italics: p < 0.05)
MAGI1 (80) MAGI2 (24) MAGI3 (91) DAWN1 (19) DAWN2 (20) DAWN3 (58) DAWN4 (113)
LoFs (16) 0 (1.000) 0 (1.000) 0 (1.000) 0 (1.000) 0 (1.000) 0 (1.000) 3 (8.921e−05)
Mis-Ds2 (56) 1 (0.199) 0 (1.000) 0 (1.000) 1 (0.051) 0 (1.000) 2 (0.011) 0 (1.000)
High-5HT_LoFs (5) 0 (1.000) 0 (1.000) 0 (1.000) 0 (1.000) 0 (1.000) 0 (1.000) 0 (1.000)
High-5HT_Mis-D2(10) 0 (1.000) 0 (1.000) 0 (1.000) 0 (1.000) 0 (1.000) 0 (1.000) 0 (1.000)
Normal-5HT_LoFs (8) 0 (1.000) 0 (1.000) 0 (1.000) 0 (1.000) 0 (1.000) 0 (1.000) 3 (9.216e−06)
Normal-5HT_Mis-D2 (38) 1 (0.140) 0 (1.000) 0 (1.000) 1 (0.035) 0 (1.000) 2 (5.280e−03) 0 (1.000)
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disease gene sets in ASD. After correcting for gene
length, RAV gene sets showed no evidence to support
enrichment amongst the various functional/disease gene
sets (Additional file 1: Table S7), likely due to some
combination of small sample size and predicted weaker
effects of RAVs (relative to DNVs) in conferring ASD
risk.
RAVs associated with hyperserotonemia
We applied GSEA to selected functional RAVs that, we
envisioned, are more likely to be enriched in the High-
5HT group (“Methods”) on the same functional/disease
gene sets, correcting for the gene length bias. We ob-
served no significant enrichment among any gene sets,
except a trend (p = 0.051) towards significance in FMRP
targets (Table 5). We then used a gene list correspond-
ing to loci from a recent study of both transmitted and
de novo variants in ASD [11]. Termed TADA-1, this
analysis from the Autism Sequencing Consortium
identified a set of 33 hcASD risk loci. Using this gene
set, we observed significant enrichment for RAV-
containing genes from this ACE sample (p = 0.03)
(Table 5). The significance level is not as striking as that
observed for DNVs (Table 1), likely owing to the smaller
sample size of the WE subset of ACE and the weaker ef-
fect of RAVs compared to those from DNVs. Two genes,
electron transfer flavoprotein beta subunit (ETFB) and
reelin (RELN), from the TADA-1 comparison were
found amongst the RAV gene set, and this remained sig-
nificant after correction for gene length. We also carried
out GSEA with a list termed TADA-2, an extended list
of 65 hcASD risk loci (63 are expressed at early stages of
brain development) which integrated small de novo dele-
tions with data of TADA-1 [10]. We did not observe sig-
nificance in this gene set (p = 0.34), with a possible
reason that the gene RELN, which is one of the two
overlapping genes in 33 TADA-1 hcASD risk genes, is
not included in the 65 TADA-2 genes. Of note, RELN
has been implicated in ASD based on numerous studies
Table 4 NGSEA to identify novel signals in different groups of DNVs (italics: p < 0.05)
AutDB Recur MAGI1 MAGI2 MAGI3 DAWN1 DAWN2 DAWN3 DAWN4
LoFs 0.838 0.07 0.225 0.326 0.224 0.187 0.52 0.502 0.748
Mis-D2 0.762 0.135 0.026 0.347 0.371 0.083 0.274 0.353 0.055
High-5HT_Func 0.734 0.467 0.178 0.759 0.83 0.027 0.335 0.376 0.244
High-5HT_LoFs 0.925 0.234 0.746 0.713 0.637 0.039 0.653 0.82 0.755
Normal-5HT_LoFs 0.481 0.046 0.139 0.147 0.104 0.33 0.801 0.233 0.506
High-5HT_Mis-D2 0.552 0.512 0.098 0.637 0.748 0.04 0.187 0.235 0.137
Normal-5HT_Mis-D2 0.612 0.1 0.031 0.249 0.25 0.174 0.207 0.329 0.035
Fig. 2 Network plot between High-5HT LoF DNV genes and the
genes in DAWN-1 module. Blue: High-5HT LoF DNV genes; green:
genes in DAWN-1 module; red: neighbor genes that connect LoF
DNV genes and genes in DAWN-1. The network shown is PINA
Fig. 3 Network plot between High-5HT Mis-D2 DNV genes and the
genes in DAWN-1 module. Blue: High-5HT Mis-D2 DNV genes; green:
genes in DAWN-1; red: neighbor genes that connect Mis-D2 and
DAWN-1. The network used is PINA
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[71]. As a control, we also performed GSEA on the
RAVs that are enriched in Normal-5HT group
(“Methods”), and there is no enrichment in all func-
tional/disease gene sets (Additional file 1: Table S7). We
further carried out network-based enrichment analysis
of the candidate RAV genes, using the same two sets of
network modules and did not observe the enrichment
patterns observed for DNVs.
RAV burden in serotonin pathway genes
We then tested whether rare variants in serotonin path-
way genes were associated with ASD by carrying out the
gTDT. Because receptors represent one major category
of proteins, we elected to select this functional axis as
the basis for subdividing 5-HT-related genes for tests of
transmission. Thus, we tested 5HT-receptor genes as one
group and the remaining genes as the Non-Receptor group
(“Methods”). We observed a significant over-transmission
of rare functional alleles in the Non-Receptor group of
genes (Transmitted: Non-Transmission = 26:13, p = 0.042),
which largely encode presynaptic proteins (e.g., SLC6A4,
ITGB3). In contrast to functional variants, synonymous
variants exhibit approximately equal transmissions,
consistent with the null expectation (62:60, p = 0.865).
Functional variants in the Receptor group showed sig-
nificant under-transmission (1:9, p = 0.021), although
the total allele count is small. In contrast, there is no
evidence for transmission distortion in the Receptor
group for synonymous variants (28:36, p = 0.346). We
also carried out gTDT on the gene set combining
both Receptor and Non-Receptor groups and did not
observe significance (p = 0.484).
Discussion
ASD is a genetically heterogeneous disorder with esti-
mates of 1000 or more genes involved in disease eti-
ology. This heterogeneity poses great challenges to
identify individually significant risk loci. This challenge
is particularly pronounced for DNVs, as mutation rates
are extremely low to observe independent de novo mu-
tations in the same gene in a given cohort. LoF DNVs in
ASD probands, although rare, are likely to have large ef-
fects when predisposing ASD risk, and therefore more
likely to identify risk genes. Accordingly, when recur-
rence of LoF DNM in the same genes is seen in a cohort
of probands, it is a strong indicator of that gene’s contri-
bution to ASD risk. In this study, we have a very limited
sample size compared to other consortium-level data-
sets, and unsurprisingly did not observe recurrent/inde-
pendent DNVs in a gene within our data. Instead, we
combined our DNVs with those from previous studies
for recurrence analysis. We identified one new recurrent
gene, USP15, as a novel ASD candidate gene, and pro-
vided further supporting evidence for two other known
recurrent DNV genes (FOXP1 and KDM5B). FOXP1 has
been linked to several cognitive disorders, and its dele-
tion causes autism-like behaviors in mice [72]. KDM5B
harbored LoF DNVs in each of two other study cohorts
(two in SSC, one in ASC), and probands with KDM5B
LoF DNVs were shown to have lower non-verbal IQ
[64]. We note that de novo LoF DNVs in KDM5B were
also observed in two unaffected (unrelated) siblings in
the SSC, suggesting incomplete penetrance. USP15 acts
as deubiquitinating enzyme on transforming growth
factor-beta (TGF-β) and bone morphogenetic protein
(BMP) stimulated R-SMADs (receptor-regulated intra-
cellular proteins that transduce extracellular signals). We
note that both TGF-β and BMP signaling are involved in
differentiation of serotonergic neurons [73], but the role
of USP15 in ASD is unclear. With accumulating ASD
exome or whole genome sequencing being made public,
leveraging previously reported DNVs is an effective strat-
egy for clearly establishing the role of novel risk genes in
ASD.
In this study, we implemented several approaches to
tackle heterogeneity. First, we separated established ASD
genes into network modules that likely represent more
homogenous functions. The second was to leverage 5-
HT as an endophenotype.
Genetic variants implicated in both hyperserotonemia
and ASD are enriched in the subset of probands with
hyperserotonemia so that we are equipped with in-
creased power to detect ASD genes that function
Table 5 GSEA of RAVs in the High-5HT group before and after
correcting for gene length (italics: p < 0.05)
Before correction After correction
RBFOX1-1 (186) 1 (0.413) 0.5
RBFOX1-2 (547) 3 (0.204) 0.57
FMRP-1 (936) 5 (0.126) 0.68
FMRP-2 (831) 10 (9.108e−05) 0.051
ECGs (928) 3 (0.497) 0.95
Hpsd (1429) 5 (0.385) 0.46
PSD-95 (107) 0 (1.000) 1
ARC (25) 0 (1.000) 1
mGluR5 (37) 1 (0.100) 0.18
NMDAR (59) 0 (1.000) 1
Presynaptic active zone (204) 0 (1.000) 1
Presynaptic (330) 2 (0.242) 0.24
Vesicles (104) 0 (1.000) 1
CRFs (55) 1 (0.145) 0.26
HMEs (146) 0 (1.000) 1
DEs (411) 1 (0.695) 0.57
TADA-1 (33) 2 (3.958e−03) 0.03
TADA-2 (63) 1 (0.165) 0.34
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through regulating serotonin levels. Using this strategy in
our data, we were able to identify novel candidate ASD
genes not identified in previous large-scale studies that
(we imagine) might poorly represent “hyperserotonemic
ASD” risk factors. Although the significance is not striking
in NGSEA, the non-overlapping LoF and Mis-D2 genes in
the High-5HT group show enrichment in the same mod-
ule (DAWN-1). In contrast, the genes harboring func-
tional DNVs in the Normal-5HT group did not uncover
new ASD genes in NGSEA, probably due to that fact that
the majority of ASD patients have normal 5-HT, so that
genes identified in previous large-scale studies are already
more likely to represent the genes identified in the
Normal-5HT probands studied here.
In this study we focused on DNVs and RAVs, two
mechanisms that we hypothesized are involved in
serotonin-related ASD genetic etiology. It is evident that
signals due to DNVs are noticeably stronger than RAVs,
presumably due in part to the larger effect sizes for
DNVs and in part to the need to restrict analysis of
RAVs to those from European subjects. For RAVs we ob-
served significant enrichment with the TADA-1 list,
which was derived by TADA’s joint modeling of both de
novo and inherited variants in a previous study [11]. We
analyzed homozygotes and CHs separately, and it is the
CHs, not homozygotes, that showed significant enrich-
ment. For example, all of the RAV genes overlapping
with the TADA list are CHs, among which two genes
(ETFB and RELN) are in the High-5HT group and two, a
lysine methyltransferase and a calcium channel gene, are
in the Normal-5HT group (CACNA2D3 and KMT2C).
We note that the sample size of our study is small
given the context of extensive genetic heterogeneity of
ASD. For all association and enrichment analyses, we re-
ported nominal p values without correcting for multiple
testing. Varying degrees of dependency across tests
makes adjustment for multiple comparisons a challen-
ging problem, even when simulations are used to esti-
mate significance empirically. Given the overall
enrichment patterns in biologically relevant gene sets
and pathways, our analyses provide promising candi-
dates for further validation in large-scale studies.
Conclusions
Our study identified novel ASD genes and provided fur-
ther support for previously reported genes harboring
DNVs implicated in ASD. Leveraging 5-HT as an endo-
phenotype, we identified novel candidate genes related
to the TGF-β pathway and cell junction function as con-
tributing to serotonin-related ASD risk. Our study dem-
onstrated the value of 5HT as an effective
endophenotype in identification of novel ASD genes,
warranting the collection of 5-HT in probands for future
ASD genetic studies.
Additional files
Additional file 1: Table S1. List of DNVs identified in our data. Table S2.
Mean and standard deviation used for normalization of WB5HT. Table S3.
Serotonin pathway genes. Table S4. Summary of subject demographics
and phenotype data. Table S5. GSEA of LoF DNVs in ASC, SSC and ACE.
Table S6. Gene lists disrupted by different types of DNVs in the High-5HT
and the Normal-5HT groups. Table S7. GSEA of all RAVs and Normal-5HT
RAVs. (XLSX 47 kb)
Additional file 2: Figure S1. The distribution of normalized 5-HT in
parents and probands. The two vertical lines at 5-HT = 1.0 and 1.75 are
the cutoffs used to define the High group (5HT > 1.75) and the Normal-
5HT group (5HT < 1.0). (PDF 19 kb)
Additional file 3: Figure S2. The result of PCA indicates the threshold
to identify the individuals with European ancestry. Left panel: PC plot of
CEU, CHB, YRI from the 1000 Genome Project. Right panel: PC plot of our
data. (PDF 8 kb)
Additional file 4: Figure S3. Gene length distribution of functional/
disease gene sets used in GSEA. Most of gene sets have higher median
gene length than the set of all genes (background distribution). The red
line indicates the median length of all genes in the genome. (PDF 80 kb)
Additional file 5: Figure S4. Burden of RAVs in Fathers, Mothers and
Probands. (a) All RAVs. (b) Homozygous RAVs. (c) Compound heterozygous
RAVs. (PNG 430 kb)
Abbreviations
5-HT: 5-Hydroxytryptamine; ACE: Autism Center of Excellence; ASC: Autism
Sequencing Consortium; ASD: Autism spectrum disorder; CDS: Coding
sequence; CH: Compound heterozygote; CIDR: Center for Inherited Disease
Research; CNS: Central nervous system; CNV: Copy number variant;
CRF: Chromatin remodeling factors; DAWN: Detecting Association with
Networks; DEs: Differentially expressed genes; DNV: De novo variant;
Dscore: Deleteriousness score; ECG: Evolutionarily constrained gene;
FMRP: Fragile X mental retardation protein; GSEA: Gene set enrichment
analysis; GWAS: Genome-wide association studies; hcASD gene: High
confidence ASD gene; High-5HT: Group with 5-HT >1.75; HME: Histone
modification enzyme; Hpsd: Postsynapse-related genes from proteomic
profiling of human neocortical biopsies; LoF: Loss of function; MAGI: Merging
Affected Genes into Integrated networks; Mis: Missense; Mis-D2: Missense
variants with Dscore ≤2; NGSEA: Network-based gene set enrichment
analysis; Normal-5HT: Group with 5-HT <1; PDN: Propagation-based Distance
in Networks; PSD: Postsynaptic density; RAV: Recessively acting variant;
RBFOX1: RNA-binding protein, fox-1 homolog 1; SNV: Single nucleotide
variant; SSC: Simons Simplex Collection; WES: Whole exome sequencing
Acknowledgements
Expert technical assistance was provided by Kathleen Hennessy, Kelley
Moore, and Zengping Hao. We would like to thank the individuals with ASD
and their family members for their participation.
Funding
The UIC Autism Center of Excellence was supported by P50HD055751 (LD,
SJ, NC, EC, JS) from NICHD/NINDS/NIEHS. Sequencing services were provided
by the Center for Inherited Disease Research (CIDR) through X01 HG007235.
CIDR is fully funded through a federal contract from the National Institutes of
Health to The Johns Hopkins University, contract number HHSN268201200008I.
The study was also supported by R01 MH089482 (JS), P50MH094267 (EC, NC)
and a Lever Award from the Chicago Biomedical Consortium. The analysis of
the data was supported by R01HG006857 (RC, QW, and BL).
Availability of data and materials
The datasets generated and/or analyzed during the current study are available
in the dbGaP repository under dbGaP study accession phs000712.v1.p1 (http://
www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000712.
v1.p1), and at the National Database for Autism Research: NDARCOL0000001,
Study #416 (http://dx.doi.org/10.15154/1271285).
Chen et al. Molecular Autism  (2017) 8:14 Page 10 of 12
Authors’ contributions
RC, LD, NC, EC, JS, and BL conceived and designed the study. RC carried out
the major analyses. LD and QW contributed to data processing. SG, SJ, and
MP managed patient samples and clinical data. EC, JS, and BL supervised the
study. RC, SD, EC, JS, and BL wrote the manuscript. All authors read and
approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
A description of the study was provided to all participants prior to obtaining
written informed consent. The study and consent procedures were approved
by the University of Illinois at Chicago IRB (protocol# 2007-0239) and by the
Vanderbilt IRB (protocol# 010143).
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Molecular Physiology & Biophysics, Vanderbilt University, Nashville, TN, USA.
2Vanderbilt Genetics Institute, Vanderbilt University, Nashville, TN, USA.
3Division of Genetic Medicine, Department of Medicine, Vanderbilt University,
Nashville, TN, USA. 4Department of Psychiatry, University of Illinois at
Chicago, Chicago, IL, USA. 5Department of Psychiatry, University of
Minnesota, Minneapolis, MN, USA.
Received: 30 August 2016 Accepted: 10 March 2017
References
1. Christensen DL, Baio J, Braun KV, Bilder D, Charles J, Constantino JN, Daniels
J, Durkin MS, Fitzgerald RT, Kurzius-Spencer M, et al. Prevalence and
characteristics of autism spectrum disorder among children aged 8 years -
autism and developmental disabilities monitoring network, 11 sites, United
States, 2012. MMWR Surveill Summ. 2016;65:1–23.
2. Tick B, Bolton P, Happe F, Rutter M, Rijsdijk F. Heritability of autism spectrum
disorders: a meta-analysis of twin studies. J Child Psychol Psychiatry. 2016;
57:585–95.
3. Klei L, Sanders SJ, Murtha MT, Hus V, Lowe JK, Willsey AJ, Moreno-De-Luca
D, Yu TW, Fombonne E, Geschwind D, et al. Common genetic variants,
acting additively, are a major source of risk for autism. Mol Autism. 2012;3:9.
4. Wang K, Zhang HT, Ma DQ, Bucan M, Glessner JT, Abrahams BS, Salyakina D,
Imielinski M, Bradfield JP, Sleiman PMA, et al. Common genetic variants on
5p14.1 associate with autism spectrum disorders. Nature. 2009;459:528–33.
5. Ma DQ, Salyakina D, Jaworski JM, Konidari I, Whitehead PL, Andersen AN,
Hoffman JD, Slifer SH, Hedges DJ, Cukier HN, et al. A genome-wide
association study of autism reveals a common novel risk locus at 5p14.1.
Ann Hum Genet. 2009;73:263–73.
6. Weiss LA, Arking DE, Consortium JHA. A genome-wide linkage and
association scan reveals novel loci for autism. Nature. 2009;461:802–U862.
7. Salyakina D, Ma DQ, Jaworski JM, Konidari I, Whitehead PL, Henson R,
Martinez D, Robinson JL, Sacharow S, Wright HH, et al. Variants in
several genomic regions associated with asperger disorder. Autism Res.
2010;3:303–10.
8. Hussman JP, Chung RH, Griswold AJ, Jaworski JM, Salyakina D, Ma DQ,
Konidari I, Whitehead PL, Vance JM, Martin ER, et al. A noise-reduction
GWAS analysis implicates altered regulation of neurite outgrowth and
guidance in autism. Mol Autism. 2011;2(1):1.
9. Anney R, Klei L, Pinto D, Regan R, Conroy J, Magalhaes TR, Correia C,
Abrahams BS, Sykes N, Pagnamenta AT, et al. A genome-wide scan for
common alleles affecting risk for autism. Hum Mol Genet. 2010;19:4072–82.
10. Sanders SJ, Xin H, Willsey AJ, Ercan-Sencicek AG, Samocha KE, Cicek AE,
Murtha MT, Bal VH, Bishop SL, Shan D, et al. Insights into autism spectrum
disorder genomic architecture and biology from 71 Risk Loci. Neuron. 2015;
87:1215–33.
11. De Rubeis S, He X, Goldberg AP, Poultney CS, Samocha K, Cicek AE, Kou Y,
Liu L, Fromer M, Walker S, et al. Synaptic, transcriptional and chromatin
genes disrupted in autism. Nature. 2014;515:209–15.
12. Gottesman II, Gould TD. The endophenotype concept in psychiatry:
etymology and strategic intentions. Am J Psychiatry. 2003;160:636–45.
13. Ruggeri B, Sarkans U, Schumann G, Persico AM. Biomarkers in autism
spectrum disorder: the old and the new. Psychopharmacology (Berl). 2014;
231:1201–16.
14. Walsh P, Elsabbagh M, Bolton P, Singh I. In search of biomarkers for autism:
scientific, social and ethical challenges. Nat Rev Neurosci. 2011;12:603–12.
15. Katsui T, Okuda M, Usuda S, Koizumi T. Kinetics of 3H-serotonin uptake by
platelets in infantile autism and developmental language disorder
(including five pairs of twins). J Autism Dev Disord. 1986;16:69–76.
16. Cook EH, Leventhal BL. The serotonin system in autism. Curr Opin Pediatr.
1996;8:348–54.
17. Gabriele S, Sacco R, Persico AM. Blood serotonin levels in autism spectrum
disorder: a systematic review and meta-analysis. Eur
Neuropsychopharmacol. 2014;24:919–29.
18. Schain RJ, Freedman DX. Studies on 5-hydroxyindole metabolism in autistic
and other mentally retarded children. J Pediatr. 1961;58:315–20.
19. Mulder EJ, Anderson GM, Kema IP, de Bildt A, van Lang ND, den Boer JA,
Minderaa RB. Platelet serotonin levels in pervasive developmental disorders
and mental retardation: diagnostic group differences, within-group
distribution, and behavioral correlates. J Am Acad Child Adolesc Psychiatry.
2004;43:491–9.
20. Abramson RK, Wright HH, Carpenter R, Brennan W, Lumpuy O, Cole E,
Young SR. Elevated blood serotonin in autistic probands and their 1st-
degree relatives. J Autism Dev Disord. 1989;19:397–407.
21. Leboyer M, Philippe A, Bouvard M, Guilloud-Bataille M, Bondoux D,
Tabuteau F, Feingold J, Mouren-Simeoni MC, Launay JM. Whole blood
serotonin and plasma beta-endorphin in autistic probands and their first-
degree relatives. Biol Psychiatry. 1999;45:158–63.
22. Piven J, Palmer P. Psychiatric disorder and the broad autism phenotype:
evidence from a family study of multiple-incidence autism families. Am J
Psychiatry. 1999;156:557–63.
23. Cook EH, Arora RC, Anderson GM, Berrykravis EM, Yan SY, Yeoh HC, Sklena
PJ, Charak DA, Leventhal BL. Platelet serotonin studies in hyperserotonemic
relatives of children with autistic disorder. Life Sci. 1993;52:2005–15.
24. Abney M, McPeek MS, Ober C. Broad and narrow heritabilities of quantitative
traits in a founder population. Am J Hum Genet. 2001;68:1302–7.
25. Chugani DC, Muzik O, Rothermel R, Behen M, Chakraborty P, Mangner T, da
Silva EA, Chugani HT. Altered serotonin synthesis in the
dentatothalamocortical pathway in autistic boys. Ann Neurol. 1997;42:666–9.
26. Chugani DC, Muzik O, Behen M, Rothermel R, Janisse JJ, Lee J, Chugani HT.
Developmental changes in brain serotonin synthesis capacity in autistic and
nonautistic children. Ann Neurol. 1999;45:287–95.
27. Chugani DC. Role of altered brain serotonin mechanisms in autism. Mol
Psychiatry. 2002;7 Suppl 2:S16–17.
28. McDougle CJ, Naylor ST, Cohen DJ, Aghajanian GK, Heninger GR, Price LH.
Effects of tryptophan depletion in drug-free adults with autistic disorder.
Arch Gen Psychiatry. 1996;53:993–1000.
29. Yang CJ, Tan HP, Du YJ. The developmental disruptions of serotonin
signaling may involved in autism during early brain development.
Neuroscience. 2014;267:1–10.
30. Sutcliffe JS, Delahanty RJ, Prasad HC, McCauley JL, Han Q, Jiang L, Li C,
Folstein SE, Blakely RD. Allelic heterogeneity at the serotonin transporter
locus (SLC6A4) confers susceptibility to autism and rigid-compulsive
behaviors. Am J Hum Genet. 2005;77:265–79.
31. Stone JL, Merriman B, Cantor RM, Yonan AL, Gilliam TC, Geschwind DH,
Nelson SF. Evidence for sex-specific risk alleles in autism spectrum disorder.
Am J Hum Genet. 2004;75:1117–23.
32. Cantor RM, Kono N, Duvall JA, Alvarez-Retuerto A, Stone JL, Alarcon M,
Nelson SF, Geschwind DH. Replication of autism linkage: fine-mapping peak
at 17q21. Am J Hum Genet. 2005;76:1050–6.
33. Veenstra-VanderWeele J, Muller CL, Iwamoto H, Sauer JE, Owens WA, Shah CR,
Cohen J, Mannangatti P, Jessen T, Thompson BJ, et al. Autism gene variant
causes hyperserotonemia, serotonin receptor hypersensitivity, social impairment
and repetitive behavior. Proc Natl Acad Sci U S A. 2012;109:5469–74.
34. Morrow EM, Yoo SY, Flavell SW, Kim TK, Lin Y, Hill RS, Mukaddes NM, Balkhy
S, Gascon G, Hashmi A, et al. Identifying autism loci and genes by tracing
recent shared ancestry. Science. 2008;321:218–23.
Chen et al. Molecular Autism  (2017) 8:14 Page 11 of 12
35. Li H, Durbin R. Fast and accurate short read alignment with Burrows-
Wheeler transform. Bioinformatics. 2009;25:1754–60.
36. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A,
Garimella K, Altshuler D, Gabriel S, Daly M, DePristo MA. The Genome
Analysis Toolkit: a MapReduce framework for analyzing next-generation
DNA sequencing data. Genome Res. 2010;20:1297–303.
37. DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, Philippakis
AA, del Angel G, Rivas MA, Hanna M, et al. A framework for variation
discovery and genotyping using next-generation DNA sequencing data. Nat
Genet. 2011;43:491–8.
38. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic
variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38:e164.
39. Wei Q, Zhan X, Zhong X, Liu Y, Han Y, Chen W, Li B. A Bayesian framework
for de novo mutation calling in parents-offspring trios. Bioinformatics. 2015;
31:1375–81.
40. Chen R, Wei Q, Zhan X, Zhong X, Sutcliffe JS, Cox NJ, Cook EH, Li C, Chen
W, Li B. A haplotype-based framework for group-wise transmission/
disequilibrium tests for rare variant association analysis. Bioinformatics. 2015;
31:1452–9.
41. Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls.
Arch Dis Child. 1969;44:291–303.
42. Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in
boys. Arch Dis Child. 1970;45:13–23.
43. McBride PA, Anderson GM, Hertzig ME, Snow ME, Thompson SM, Khait VD,
Shapiro T, Cohen DJ. Effects of diagnosis, race, and puberty on platelet
serotonin levels in autism and mental retardation. J Am Acad Child Adolesc
Psychiatry. 1998;37:767–76.
44. Voineagu I, Wang X, Johnston P, Lowe JK, Tian Y, Horvath S, Mill J, Cantor
RM, Blencowe BJ, Geschwind DH. Transcriptomic analysis of autistic brain
reveals convergent molecular pathology. Nature. 2011;474:380–4.
45. Zhang C, Zhang Z, Castle J, Sun S, Johnson J, Krainer AR, Zhang MQ.
Defining the regulatory network of the tissue-specific splicing factors Fox-1
and Fox-2. Genes Dev. 2008;22:2550–63.
46. Ascano Jr M, Mukherjee N, Bandaru P, Miller JB, Nusbaum JD, Corcoran DL,
Langlois C, Munschauer M, Dewell S, Hafner M, et al. FMRP targets distinct
mRNA sequence elements to regulate protein expression. Nature. 2012;492:
382–6.
47. Darnell JC, Van Driesche SJ, Zhang C, Hung KY, Mele A, Fraser CE, Stone EF,
Chen C, Fak JJ, Chi SW, et al. FMRP stalls ribosomal translocation on mRNAs
linked to synaptic function and autism. Cell. 2011;146:247–61.
48. Samocha KE, Robinson EB, Sanders SJ, Stevens C, Sabo A, McGrath LM,
Kosmicki JA, Rehnstrom K, Mallick S, Kirby A, et al. A framework for the
interpretation of de novo mutation in human disease. Nat Genet. 2014;
46(9):944–50.
49. Bayes A, van de Lagemaat LN, Collins MO, Croning MD, Whittle IR,
Choudhary JS, Grant SG. Characterization of the proteome, diseases and
evolution of the human postsynaptic density. Nat Neurosci. 2011;14:19–21.
50. Pirooznia M, Wang T, Avramopoulos D, Valle D, Thomas G, Huganir RL, Goes
FS, Potash JB, Zandi PP. SynaptomeDB: an ontology-based knowledgebase
for synaptic genes. Bioinformatics. 2012;28:897–9.
51. Shipra A, Chetan K, Rao MR. CREMOFAC—a database of chromatin
remodeling factors. Bioinformatics. 2006;22:2940–4.
52. Khare SP, Habib F, Sharma R, Gadewal N, Gupta S, Galande S. HIstome–a
relational knowledgebase of human histone proteins and histone modifying
enzymes. Nucleic Acids Res. 2012;40:D337–342.
53. Parikshak NN, Luo R, Zhang A, Won H, Lowe JK, Chandran V, Horvath S,
Geschwind DH. Integrative functional genomic analyses implicate specific
molecular pathways and circuits in autism. Cell. 2013;155:1008–21.
54. Willsey AJ, Sanders SJ, Li M, Dong S, Tebbenkamp AT, Muhle RA, Reilly SK,
Lin L, Fertuzinhos S, Miller JA, et al. Coexpression networks implicate human
midfetal deep cortical projection neurons in the pathogenesis of autism.
Cell. 2013;155:997–1007.
55. Hormozdiari F, Penn O, Borenstein E, Eichler EE. The discovery of integrated
gene networks for autism and related disorders. Genome Res. 2015;25:142–54.
56. Glaab E, Baudot A, Krasnogor N, Schneider R, Valencia A. EnrichNet:
network-based gene set enrichment analysis. Bioinformatics. 2012;28:i451–7.
57. Can T, Çamoǧlu O, Singh AK. Analysis of protein-protein interaction
networks using random walks. In: Proceedings of the 5th international
workshop on Bioinformatics. Chicago: ACM; 2005. p. 61–8.
58. Chipman KC, Singh AK. Predicting genetic interactions with random walks
on biological networks. BMC Bioinformatics. 2009;10:17.
59. Cowley MJ, Pinese M, Kassahn KS, Waddell N, Pearson JV, Grimmond SM,
Biankin AV, Hautaniemi S, Wu J. PINA v2.0: mining interactome modules.
Nucleic Acids Res. 2012;40:D862–865.
60. Neale BM, Kou Y, Liu L, Ma'ayan A, Samocha KE, Sabo A, Lin CF, Stevens C,
Wang LS, Makarov V, et al. Patterns and rates of exonic de novo mutations
in autism spectrum disorders. Nature. 2012;485:242–5.
61. Levin-Decanini T, Maltman N, Francis SM, Guter S, Anderson GM, Cook EH,
Jacob S. Parental broader autism subphenotypes in ASD affected families:
relationship to gender, child’s symptoms, SSRI treatment, and platelet
serotonin. Autism Res. 2013;6:621–30.
62. Davis LK, Maltman N, Mosconi MW, Macmillan C, Schmitt L, Moore K,
Francis SM, Jacob S, Sweeney JA, Cook EH. Rare inherited A2BP1 deletion in
a proband with autism and developmental hemiparesis. Am J Med Genet A.
2012;158A:1654–61.
63. Werling DM, Geschwind DH. Sex differences in autism spectrum disorders.
Curr Opin Neurol. 2013;26:146–53.
64. Iossifov I, O'Roak BJ, Sanders SJ, Ronemus M, Krumm N, Levy D, Stessman HA,
Witherspoon KT, Vives L, Patterson KE, et al. The contribution of de novo
coding mutations to autism spectrum disorder. Nature. 2014;515:216–21.
65. Sanders SJ, Murtha MT, Gupta AR, Murdoch JD, Raubeson MJ, Willsey AJ,
Ercan-Sencicek AG, DiLullo NM, Parikshak NN, Stein JL, et al. De novo
mutations revealed by whole-exome sequencing are strongly associated
with autism. Nature. 2012;485:237–U124.
66. Kremer EJ, Pritchard M, Lynch M, Yu S, Holman K, Baker E, Warren ST,
Schlessinger D, Sutherland GR, Richards RI. Mapping of DNA instability at the
Fragile-X to a trinucleotide repeat sequence P(Ccg)N. Science. 1991;252:1711–4.
67. Verkerk AJ, Pieretti M, Sutcliffe JS, Fu YH, Kuhl DP, Pizzuti A, Reiner O,
Richards S, Victoria MF, Zhang FP, et al. Identification of a gene (FMR-1)
containing a CGG repeat coincident with a breakpoint cluster region
exhibiting length variation in fragile X syndrome. Cell. 1991;65:905–14.
68. Vincent A, Heitz D, Petit C, Kretz C, Oberle I, Mandel JL. Abnormal pattern
detected in fragile-X patients by pulsed-field gel electrophoresis. Nature.
1991;349:624–6.
69. Lal D, Pernhorst K, Klein KM, Reif P, Tozzi R, Toliat MR, Winterer G, Neubauer
B, Nurnberg P, Rosenow F, et al. Extending the phenotypic spectrum of
RBFOX1 deletions: sporadic focal epilepsy. Epilepsia. 2015;56:e129–133.
70. Basu SN, Kollu R, Banerjee-Basu S. AutDB: a gene reference resource for
autism research. Nucleic Acids Res. 2009;37:D832–836.
71. Lammert DB, Howell BW. RELN Mutations in autism spectrum disorder.
Front Cell Neurosci. 2016;10:84.
72. Bacon C, Schneider M, Le Magueresse C, Froehlich H, Sticht C, Gluch C, Monyer
H, Rappold GA. Brain-specific Foxp1 deletion impairs neuronal development
and causes autistic-like behaviour. Mol Psychiatry. 2015;20:632–9.
73. Yamasaki A, Kasai A, Toi A, Kurita M, Kimoto S, Hayata-Takano A, Nakazawa T,
Nagayasu K, Shintani N, Hashimoto R, et al. Identification of the role of bone
morphogenetic protein (BMP) and transforming growth factor-beta (TGF-beta)
signaling in the trajectory of serotonergic differentiation in a rapid assay in
mouse embryonic stem cells in vitro. J Neurochem. 2015;132:418–28.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Chen et al. Molecular Autism  (2017) 8:14 Page 12 of 12
